[1]
R. Cao, W. Du, and B. Lin, “Comparison and Synergy of iVAC and CRISPR-Related Tumor Immune Strategies: Value Reassessment Under A Zero Genome Risk Reference”, IJBLS, vol. 17, no. 2, pp. 44–51, Nov. 2026, doi: 10.54097/pnqcf426.